Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer
MTX240's mechanistic novelty may give it a long-awaited edge in treatments for gastrointestinal stromal tumors (GIST) Meg Flippin, Benzinga Staff Writer CARDIFF, UK / ACCESS Newswire / February 19, 2026 / Biodexa Pharmaceuticals PLC (NASDAQ …